Neurophet, an AI company specializing in diagnosing and treating brain diseases, said on the 9th that it signed a supply contract for its neurodegeneration imaging analysis software "Neurophet AQUA" with the Tokyo Metropolitan Institute of Gerontology in Japan.
Neurophet AQUA performs ultra-fast quantitative analysis of a patient's brain MRI, quantifying brain atrophy and white matter degeneration to provide customized analysis reports for neurodegenerative diseases such as Alzheimer's disease and vascular dementia.
The company said it will begin a full-fledged push into the Japanese market through this contract. The Tokyo Metropolitan Institute of Gerontology, which signed the contract, is a research institution specializing in geriatrics, and Atsushi Iwata (Atsushi Iwata, M.D., Ph.D.), whom Neurophet recruited as a scientific advisory board member, currently serves as deputy director.
Bin Jun-gil, co-CEO of Neurophet, said, "By supplying Neurophet AQUA to a Japanese research institution with competitiveness in Alzheimer's disease research, we have established a bridgehead for entering the Japanese market," adding, "We plan to continue expanding distribution channels in Japan on this momentum."
Founded in 2016, Neurophet was established by co-CEOs Bin Jun-gil and Kim Dong-hyun, who developed a next-generation neuro-navigation system at the Gwangju Institute of Science and Technology (GIST).